New drug cocktail aims to boost kidney cancer surgery success

NCT ID NCT07627464

Not yet recruiting Disease control Sponsor: Tianjin Medical University Cancer Institute and Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tests whether giving two drugs (anlotinib and benmelstobart) before surgery can improve outcomes for people with localized kidney cancer. About 144 participants will either receive the drug combo followed by partial nephrectomy, or surgery alone. The main goal is to see if the combo helps preserve kidney function and reduces complications.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: anlotinib hydrochloride and benmelstobart
What this could lead to: If successful, this approach could improve kidney function preservation and surgical outcomes for patients with localized kidney cancer, potentially reducing the need for more extensive surgery.
What could go wrong: This is an early Phase 2 trial with only 144 participants, so results may not apply to all patients. The combination therapy may cause side effects and may not improve outcomes compared to surgery alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALIZED RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RENAL CELL CARCINOMA (RCC)

Contacts and locations

Locations

Huadong Hospital Affiliated to Fudan University

Shanghai, China
Hunan Provincial Cancer Hospital

Changsha, China
Jilin Provincial Cancer Hospital

Changchun, China
Liaoning Provincial Cancer Hospital

Shenyang, China
Nanjing Drum Tower Hospital

Nanjing, China
Peking University Third Hospital

Beijing, China
Shanxi Province Cancer Hospital

Taiyuan, China
The Affiliated Hospital of Qingdao University

Qingdao, China
The First Affiliated Hospital of Guangxi Medical University

Nanning, China
The First Affiliated Hospital of Zhengzhou University

Zhengzhou, China
The First Affiliated Hospital, Zhejiang University School of Medicine

Hangzhou, China
Tianjin Medical University Cancer Institute and Hospital

Tianjin, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, China
Yunnan Provincial Cancer Hospital

Kunming, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.